Findings

What do systematic reviews say?

7 questions · 7 findings · 2 reviews

No studies found 2 · 28.6%GRADE not reported 0 · 0%Very low 0 · 0%Low 5 · 71.4%Moderate 0 · 0%High 0 · 0%

Mortality by day 30 · non‐hospitalised individuals with COVID‐19

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 101 participants
Low

Mortality by day 60 · non‐hospitalised individuals with COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mortality by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)

Bamlanivimab showed no clear difference in mortality by day 30 compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 1.39 [0.4, 4.83]
1 study · 314 participants
Low

Mortality by day 90 · hospitalised individuals with COVID‐19 (moderate to severe disease)

Bamlanivimab showed no clear difference in mortality by day 90 compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
HR 1.09 [0.49, 2.43]
1 study · 314 participants
Low

All‐cause mortality by day 60 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2

Bamlanivimab showed no clear difference in all‐cause mortality by day 60 compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 2022 · Cochrane Headline outcomes only
RR 0.83 [0.25, 2.7]
1 study · 966 participants
Low

Mortality by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Bamlanivimab/etesevimab may leads to lower mortality by day 30 compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 0.05 [0, 0.81]
1 study · 1035 participants
Low

Mortality by day 60 ‐ not reported · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found